No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SRCL Stericycle
- 47.580
- -2.290-4.59%
Trading Apr 25 10:18 ET
4.41BMarket Cap-206869P/E (TTM)
49.050High46.360Low180.19KVolume47.910Open49.870Pre Close8.62MTurnover0.20%Turnover RatioLossP/E (Static)92.78MShares57.06052wk High1.75P/B4.39BFloat Cap37.78052wk Low--Dividend TTM92.26MShs Float151.570Historical High--Div YieldTTM5.39%Amplitude1.813Historical Low47.847Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Stericycle Q1 24 Earnings Conference Call At 9:00 AM ET
Express News | Stericycle Inc: We Remain on Track to Achieve Our Full-Year 2024 Guidance and Long-Term Outlook
Stericycle Q2 2024 GAAP EPS $0.57, Inline, Sales $664.900M Miss $679.277M Estimate
Stericycle (NASDAQ:SRCL) reported quarterly earnings of $0.57 per share which met the analyst consensus estimate. This is a 16.33 percent increase over earnings of $0.49 per share from the same period
Earnings Flash (SRCL) STERICYCLE Posts Q1 Revenue $664.9M
07:05 AM EDT, 04/25/2024 (MT Newswires) -- Earnings Flash (SRCL) STERICYCLE Posts Q1 Revenue $664.9M
Express News | Stericycle Q1 Net Income USD 13.1 Million
Express News | Stericycle Q1 Adjusted Ebitda USD 116.2 Million Vs. Ibes Estimate USD 115.3 Million
Comments
Stericycle's high P/S ratio may be due to expectations of a revenue turnaround. However, with weak revenue growth and a higher industry growth forecast, the elevated P/S ratio may not be justified and could fall if revenue sentiment doesn't improve. Current prices may not be reasonable unless conditions significantly improve.
Risks To Shareholder Returns Are Elevated At These Prices For Stericycle, Inc. (NASDAQ:SRCL)Repeated insider purchases of Stericycle, Inc.'s shares at near current price indicate optimism about the company's future. Despite no recent quarter insider trading, the holdings hint at alignment between insiders and shareholders, although insider ownership is not particularly high.
Stericycle's declining ROCE and capital employed may signify competitive challenges or deterioration of its business advantage, indicating that the company may have moved beyond its growth phase, causing investor concern.
Investors are let down by Stericycle's lack of profit and revenue growth. However, the company making progress amidst negative sentiment could offer an opportunity. Insiders buying shares is a good sign, yet revenue and earnings growth trends still hold more importance.
ColumnsTop upgrades and downgrades on 5/12
Upgrades
•$Albemarle(ALB.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $285 (from $215)
• $Alcon(ALC.US$ : Stephens Upgrades to Overweight from EqualWeight - PT $92 (from $86)
• $Atlantica Sustainable Infrastructure(AY.US$ : BofA Securities Upgrades to Buy from Neutral - PT $33 (from $38)
• $Coupang(CPNG.US$ : Citigroup Upgrades to Buy from Neutral - PT $15 (from $29)
• $89bio(ETNB.US$ : Raymond James Upgrades to Strong Buy from Outp...
•$Albemarle(ALB.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $285 (from $215)
• $Alcon(ALC.US$ : Stephens Upgrades to Overweight from EqualWeight - PT $92 (from $86)
• $Atlantica Sustainable Infrastructure(AY.US$ : BofA Securities Upgrades to Buy from Neutral - PT $33 (from $38)
• $Coupang(CPNG.US$ : Citigroup Upgrades to Buy from Neutral - PT $15 (from $29)
• $89bio(ETNB.US$ : Raymond James Upgrades to Strong Buy from Outp...
16
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg